Shattuck Labs Inc美股招股说明书(2026-01-22版)

Up to $75,000,000Common Stock We have entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”) relating to shares of our commonstock, $0.0001 par value per share, offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the SalesAgreement, from time to time we may offer and sell shares of our common stock through Leerink Partners, acting as sales agent. In accordance with theterms of the Sales Agreement, in this prospectus supplement and the accompanying prospectus, we are hereby registering shares of our common stock Our common stock is listed on The Nasdaq Global Select Market (“Nasdaq”) under the symbol “STTK.” On January 21, 2026, the last reported saleprice of our common stock as reported on Nasdaq was $4.44 per share. Sales of our common stock, if any, under this prospectus supplement may be made in sales deemed to be an “at the market offering” as defined in Rule415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Subject to terms of the Sales Agreement, Leerink Partners isnot required to sell any specific number or dollar amount of securities but will act as our sales agent using commercially reasonable efforts consistent Leerink Partners will be entitled to a commission of up to 3.0% of the gross sales price per share sold under the Sales Agreement. In connection with thesale of our common stock on our behalf, Leerink Partners may be deemed to be an “underwriter” within the meaning of the Securities Act and thecompensation of Leerink Partners may be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification andcontributions to Leerink Partners against certain civil liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as Investing in our common stock involves a high degree of risk. You should review carefully the risks and uncertaintiesdescribed under the heading “Risk Factors” on pageS-4 of this prospectus supplement, and under similar headings inthe documents that are incorporated by reference into this prospectus supplement and the accompanying prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities ordetermined if this prospectus supplement and the accompanying prospectus are truthful or complete. Any representation to the contrary is acriminal offense. January 22, 2026 Prospectus Supplement ABOUT THIS PROSPECTUSSPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement and the accompanying prospectus relate to an offering of shares of our common stock. Before buying any of the commonstock that we are offering, we urge you to carefully read this prospectus supplement and the accompanying prospectus, together with the informationincorporated by reference as described under the headings “Where You Can Find Additional Information” and “Incorporation of Certain Information byReference” in this prospectus supplement. These documents contain important information that you should consider when making your investment This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering of common stock and also adds to,updates and changes information contained in the accompanying prospectus and the documents incorporated by reference. The second part is theaccompanying prospectus, which gives more general information. Generally, when we refer to this prospectus, we are referring to both parts of thisdocument combined. To the extent the information contained in this prospectus supplement differs from or conflicts with the information contained inthe accompanying prospectus or any document incorporated by reference, the information in this prospectus supplement will control. If any statement in We have not, and Leerink Partners has not, authorized anyone to provide you with information different from that which is contained in or incorporatedby reference in this prospectus supplement, the accompanying prospectus and in any free writing prospectus that we may authorize for use in connectionwith this offering. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give to you.No one is making offers to sell or seeking offers to buy these securities in any jurisdiction where the offer or sale is not permitted. You should assumethat the information contained in this prospectus supplement is accurate as of the date on the front cover of this prospectus supplement only and that anyinformation we have incorporated by reference or included in the accompanying prospectus is accurate only as of the date given in the document We further note that the representations, warranties and covenants made by us in any agreement t